» Articles » PMID: 25225287

Pigment Epithelial-derived Factor (PEDF)-triggered Lung Cancer Cell Apoptosis Relies on P53 Protein-driven Fas Ligand (Fas-L) Up-regulation and Fas Protein Cell Surface Translocation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2014 Sep 17
PMID 25225287
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Pigment epithelium-derived factor (PEDF), a potent antiangiogenesis agent, has recently attracted attention for targeting tumor cells in several types of tumors. However, less is known about the apoptosis-inducing effect of PEDF on human lung cancer cells and the underlying molecular events. Here we report that PEDF has a growth-suppressive and proapoptotic effect on lung cancer xenografts. Accordingly, in vitro, PEDF apparently induced apoptosis in A549 and Calu-3 cells, predominantly via the Fas-L/Fas death signaling pathway. Interestingly, A549 and Calu-3 cells are insensitive to the Fas-L/Fas apoptosis pathway because of the low level of cell surface Fas. Our results revealed that, in addition to the enhancement of Fas-L expression, PEDF increased the sensitivity of A549 and Calu-3 cells to Fas-L-mediated apoptosis by triggering the translocation of Fas protein to the plasma membrane in a p53- and FAP-1-dependent manner. Similarly, the up-regulation of Fas-L by PEDF was also mediated by p53. Furthermore, peroxisome proliferator-activated receptor γ was determined to be the upstream regulator of p53. Together, these findings uncover a novel mechanism of tumor cell apoptosis induced by PEDF and provide a potential therapeutic strategy for tumors that are insensitive to Fas-L/Fas-dependent apoptosis because of a low level of cell surface Fas.

Citing Articles

A novel signature constructed by mitochondrial function and cell death-related gene for the prediction of prognosis in bladder cancer.

Yan Z, Liu Y, Wang M, Wang L, Chen Z, Liu X Sci Rep. 2024; 14(1):14667.

PMID: 38918587 PMC: 11199696. DOI: 10.1038/s41598-024-65594-0.


Novel plasma protein biomarkers from critically ill sepsis patients.

Van Nynatten L, Slessarev M, Martin C, Leligdowicz A, Miller M, Patel M Clin Proteomics. 2022; 19(1):50.

PMID: 36572854 PMC: 9792322. DOI: 10.1186/s12014-022-09389-3.


Upregulation of PEDF Predicts a Poor Prognosis and Promotes Esophageal Squamous Cell Carcinoma Progression by Modulating the MAPK/ERK Signaling Pathway.

Chen Z, Che D, Gu X, Lin J, Deng J, Jiang P Front Oncol. 2021; 11:625612.

PMID: 33718190 PMC: 7953146. DOI: 10.3389/fonc.2021.625612.


miR-196b-5p-mediated downregulation of FAS promotes NSCLC progression by activating IL6-STAT3 signaling.

Huang X, Xiao S, Zhu X, Yu Y, Cao M, Zhang X Cell Death Dis. 2020; 11(9):785.

PMID: 32963220 PMC: 7508872. DOI: 10.1038/s41419-020-02997-7.


Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors.

Weidle U, Birzele F, Tiefenthaler G Cancer Genomics Proteomics. 2018; 15(4):225-238.

PMID: 29976628 PMC: 6070713. DOI: 10.21873/cgp.20081.


References
1.
Chen J, Zhao W, Zhang J, Jiang W, Zhang L . [Effects of pigment epithelial derived factor gene on growth of lung cancer cell and neovascularization: experiments with lung cancer cells and chick embryos]. Zhonghua Yi Xue Za Zhi. 2009; 89(7):485-90. View

2.
Chen J, Ye L, Zhang L, Jiang W . The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol. 2009; 35(1):159-66. DOI: 10.3892/ijo_00000324. View

3.
Ivanov V, Lopez Bergami P, Maulit G, Sato T, Sassoon D, Ronai Z . FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol. 2003; 23(10):3623-35. PMC: 164761. DOI: 10.1128/MCB.23.10.3623-3635.2003. View

4.
Roy J, Pallepati P, Bettaieb A, Averill-Bates D . Acrolein induces apoptosis through the death receptor pathway in A549 lung cells: role of p53. Can J Physiol Pharmacol. 2010; 88(3):353-68. DOI: 10.1139/Y09-134. View

5.
Lee S, Shin M, Park W, Kim S, Kim H, Han J . Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999; 18(25):3754-60. DOI: 10.1038/sj.onc.1202769. View